Formed in 2010 from a merger of Oxford University and Imperial College spin-outs, this Oxfordshire firm has raised £55m to develop viruses that attack cancerous cells. In 2016 it signed a licensing deal with the US group Bristol-Myers Squibb for its pre-clinical stage treatment, NG-348. This deal — worth up to $936m in development, regulatory and sales-based milestones — helped turnover climb to £53.1m last year, thanks to a $50m upfront payment and a $15m payment when the treatment gained clinical trial approval. The firm is led by chief executive John Beadle, 53.
This profile reflects the company at time of publication and does not reflect any changes that may have subsequently occurred. Fast Track and its sponsors do not endorse, guarantee or recommend investment in any of the companies.